DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste

Information source: The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulp Necrosis

Intervention: Double Antibiotic Paste (Drug); Triple Antibiotic Paste (Drug); Mineral Trioxide Aggregate (Drug)

Phase: Phase 0

Status: Terminated

Sponsored by: The University of Texas Health Science Center at San Antonio

Official(s) and/or principal investigator(s):
Kenneth M Hargreaves, DDS, PhD, Principal Investigator, Affiliation: The University of Texas Health Science Center at San Antonio

Summary

The purpose of this study is to determine the treatment outcomes in permanent teeth with necrotic pulp and immature root development that undergo a regenerative procedure using a triple antibiotic paste (ciprofloxacin, metronidazole, minocycline) versus a double antibiotic paste (ciprofloxacin, metronidazole)compared to the commonly used mineral trioxide aggregate (MTA) apexification treatment.

Clinical Details

Official title: Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The primary outcome measures will be radiographic measurement of root length and dentinal wall thickness.

Secondary outcome: The secondary outcomes will be lack of clinical symptoms and crown staining.

Detailed description: Recent case series have reported positive outcomes treating necrotic immature permanent teeth with a regenerative procedure using a triple antibiotic paste (ciprofloxacin, metronidazole, minocycline). However, this method can result in considerable staining due to minocycline. In this randomized clinical trial, we will compare clinical outcomes of a triple antibiotic paste versus a double antibiotic paste (ciprofloxacin, metronidazole) intracanal medicament as compared to a standard treatment (immediate apexification with MTA) in permanent teeth with necrotic pulps and immature root development. We hypothesize there will be no significant differences between radiographic measures of root development after treatment with either the double versus triple antibiotic paste, and that both methods will produce significantly greater increases in root length and width compared to standard treatment. The primary outcome measures will be radiographic measurement of root length and dentinal wall thickness and the secondary outcomes will be lack of clinical symptoms and crown staining.

Eligibility

Minimum age: 7 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- diagnosis of pulpal necrosis with apical periodontitis

- patients 7-60 years of age

- maxillary or mandibular restorable single rooted immature permanent tooth

with open apices

- acceptance of treatment plan with revascularization procedure

- healthy patient (ASA Class I or II physical status) with no systemic health problems

Exclusion Criteria:

- non-restorable teeth

- patients with ASA Class III or IV physical status (Immuno-compromised patients

including patients who self-report to be a carrier of HIV, undergoing steroid therapy, or those who self-report with genetic or systemic diseases that could result in reduced immune response.

- child subjects unable to give assent

Locations and Contacts

University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States
Additional Information

Starting date: April 2009
Last updated: March 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017